High Viral Specific Antibody Convalescent Plasma Effectively Neutralizes SARS-CoV-2 Variants of Concern [preprint]
Beck, Evan J
Tobian, Aaron Ar
Chiklis, Gregory R
Wiltshire, Timothy D
Dietz, Allan B
Gniadek, Thomas J
Bloch, Evan M
Cachay, Edward R
Meisenberg, Barry R
Huaman, Moises A
Heath, Sonya L
Levine, Adam C
Paxton, James H
Gerber, Jonathan M.
Gebo, Kelly A
Sullivan, David J
UMass Chan AffiliationsMedicine
MetadataShow full item record
AbstractThe ongoing evolution of SARS-Co-V2 variants to omicron severely limits available effective monoclonal antibody therapies. Effective drugs are also supply limited. Covid-19 convalescent plasma (CCP) qualified for high antibody levels effectively reduces immunocompetent outpatient hospitalization. The FDA currently allows outpatient CCP for the immunosuppressed. Viral specific antibody levels in CCP can range ten-to hundred-fold between donors unlike the uniform viral specific monoclonal antibody dosing. Limited data are available on the efficacy of polyclonal CCP to neutralize variants. We examined 108 pre-delta/pre-omicron donor units obtained before March 2021, 20 post-delta COVID-19/post-vaccination units and one pre-delta/pre-omicron hyperimmunoglobulin preparation for variant specific virus (vaccine-related isolate (WA-1), delta and omicron) neutralization correlated to Euroimmun S1 IgG antibody levels. We observed a 2-to 4-fold and 20-to 40-fold drop in virus neutralization from SARS-CoV-2 WA-1 to delta or omicron, respectively. CCP antibody levels in the upper 10% of the 108 donations as well as 100% of the post-delta COVID-19/post-vaccination units and the hyperimmunoglobulin effectively neutralized all three variants. High-titer CCP neutralizes SARS-CoV-2 variants despite no previous donor exposure to the variants. Key points: All of the post-delta COVID-19/post vaccination convalescent plasma effectively neutralizes the omicron and delta variants.High-titer CCP and hyperimmunoglobulin neutralizes SARS-CoV-2 variants despite no previous donor exposure to the variants.
SourceLi M, Beck EJ, Laeyendecker O, Eby Y, Tobian AA, Caturegli P, Wouters C, Chiklis GR, Block W, McKie R, Joyner M, Wiltshire TD, Dietz AB, Gniadek TJ, Shapiro A, Yarava A, Lane K, Hanley D, Bloch EM, Shoham S, Cachay ER, Meisenberg BR, Huaman MA, Fukuta Y, Patel B, Heath SL, Levine AC, Paxton JH, Anjan S, Gerber JM, Gebo KA, Casadevall A, Pekosz A, Sullivan DJ; CSSC group. High Viral Specific Antibody Convalescent Plasma Effectively Neutralizes SARS-CoV-2 Variants of Concern. medRxiv [Preprint]. 2022 Mar 2:2022.03.01.22271662. doi: 10.1101/2022.03.01.22271662. Update in: Blood Adv. 2022 Apr 20;: PMID: 35262085; PMCID: PMC8902868.
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/51201
NotesThis article is a preprint. Preprints are preliminary reports of work that have not been certified by peer review.
RightsThe copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.